|
Huperzine A in Alzheimer's Disease Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Huperzine A in Alzheimer's Disease conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Huperzine A in Alzheimer's Disease Clinical research trials and Huperzine A in Alzheimer's Disease health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Huperzine A in Alzheimer's Disease. Huperzine A in Alzheimer's Disease Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Huperzine A in Alzheimer's Disease clinical trial. Human subjects frequently get the finest healthcare available for their Huperzine A in Alzheimer's Disease condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "H" Clinical Trials Conditions > Huperzine A in Alzheimer's Disease  Huperzine A in Alzheimer's Disease
Huperzine A in Alzheimer's Disease
For Condition: Alzheimer Disease
Status: Recruiting
Sponsor(s): National Institute on Aging (NIA) , Alzheimer's Disease Cooperative Study (ADCS)
Synopsis: The present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect on cognitive function.
Details: Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is currently available as a nutraceutical in this country, and is being used by some U.S. clinicians to treat AD. However, there have been no controlled clinical trials outside China assessing its toxicity and efficacy. The present study will evaluate huperzine A in the treatment of AD in a randomized controlled trial of its effect on cognitive function. The primary aim of this multicenter, double-blind, placebo-controlled therapeutic Phase II trial is to determine whether treatment with huperzine A 200µg twice a day improves cognitive function in individuals with AD. Secondary aims of this study are to: a) determine whether treatment with huperzine A 400µg twice a day improves cognitive function in individuals with AD; b) determine the effect of huperzine A treatment on global clinical status, activities of daily living, and behavior in AD; c) evaluate the tolerability of huperzine A treatment at dosages of 200µg twice a day and 400µg twice a day in AD; and d) determine the relationship between blood cholinesterase activity and cognitive function in individuals with AD treated with huperzine A. A total of 150 participants will be randomly assigned to three groups of equal size. This will allow a comparison of huperzine A 200µg twice a day, huperzine A 400µg twice a day, and placebo. The primary outcome measures will be the change in score on the ADAScog at the 16 week visit. Secondary outcome measures include the ADCS clinical global impression of change (CGIC) (Schneider et al 1997) and activities of daily living (ADL) (Galasko et al 1997) scales, and the Neuropsychiatric Inventory (Cummings 1997). Volunteers must be able to participate in the study for 24 weeks and make 9 visits to the trial site.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 55 Years/
Genders: Both
Protocol Entry Criteria: The selection process is designed to allow enrollment of all people with AD who are likely to be testable at the conclusion of the study period, and who do not have concurrent medical conditions or medications that might influence cognitive testing or that would increase the risk of treatment. Women and members of minority groups are encouraged to volunteer. Inclusion Criteria: - NINDS/ADRDA criteria for probable AD. - Mini Mental State Examination between 10 and 24, inclusive. - Stable medical condition for 3 months prior to screening. - Supervision available for administration of study medications. - Study partner to accompany participant to all scheduled visits. - Fluent in English or Spanish. - Age 55 years or older. - Modified Hachinski score equal to or greater than 4. - CT or MRI since onset of memory impairment demonstrating absence of clinically significant focal lesion. - Able to complete baseline assessments. - 6 years of education, or work history sufficient to exclude mental retardation. - Able to ingest oral medication. - Stable doses of medications for 4 weeks prior to screening. - Physically acceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests. Exclusion Criteria: - History of active peptic ulcer disease within 1 year of screening. - Clinically significant cardiac arrhythmia. - Resting pulse less than 50. - Active neoplastic (cancer) disease (skin tumors other than melanoma are not excluded; participants with stable prostate cancer may be included at the discretion of the Project Director). - Use of another investigational agent within 2 months of screening. - History of clinically significant stroke. - Current evidence or history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness and/or immediate confusion after the injury, or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse. - Blindness, deafness, language difficulties or any other disability which may prevent the participant from participating or cooperating in the protocol. - Residence in a skilled nursing facility; but patients in an assited living facility are acceptable. Excluded Medications: - Use of cholinesterase inhibitors (galantamine, rivastigmine, donepezil, and tacrine) within 2 months of screening. - Regular use of narcotic analgesics (>2 doses per week) within 4 weeks of screening. - Use of medications with significant central nervous system anticholinergic activity within 2 months of screening (e.g. tricyclic antidepressants, diphenhydramine). - Use of anti-Parkinsonian medications (including Sinemet, amantadine, bromocriptine, pergolide, selegeline) within 2 months of screening. - Participation in any other investigational drug study within 2 months of screening (individuals may not participate in any other drug study while participating in this protocol). - Use of estrogen is allowed if the dose has been stable for 3 months prior to screening. - Use of vitamin E is allowed if the dose has been stable for 3 months prior to screening. - Use of memantine is allowed if the dose has been stable for 3 months prior to screening.
Total Enrollment: 150
Location and Contact Information:
Overall Study Official:
PaulAisen, Principal Investigator, Georgetown University Medical Center, Memory Disorders Program
University of California, Davis *Not yet recruiting*
Sacramento, California, 95817
United States
Not yet recruiting
Medical University of South Carolina *Not yet recruiting*
North Charleston, South Carolina, 29406
United States
Not yet recruiting
University of Texas Southwestern Medical Center *Not yet recruiting*
Dallas, Texas, 75390
United States
Not yet recruiting
University of Alabama *Not yet recruiting*
Birmingham, Alabama, 35294
United States
Not yet recruiting
Baumel-Eisner Neuromedical Institute *Not yet recruiting*
Ft. Lauderdale, Florida, 33321
United States
Not yet recruiting
New York University Medical Center *Recruiting*
New York City, New York, 10016
United States
Recruiting Suzanne Blaisdell 212-263-5708
University of South Florida *Recruiting*
Tampa, Florida, 33617
United States
Recruiting Amanda Smith 813-976-4355
Premiere Research Institute *Recruiting*
West Palm Beach, Florida, 33407
United States
Recruiting Cora Kessel 561-845-0500
Emory University *Not yet recruiting*
Atlanta, Georgia, 30329
United States
Not yet recruiting
University of Medicine and Dentistry of New Jersey *Not yet recruiting*
Piscataway, New Jersey, 08855
United States
Not yet recruiting
University of Rochester Medical Center *Not yet recruiting*
Rochester, New York, 14620
United States
Not yet recruiting
Howard University School of Medicine *Not yet recruiting*
Washington D.C., District of Columbia, 20060
United States
Not yet recruiting
Rush Alzheimer's Disease Center, Rush University Medical Center *Not yet recruiting*
Chicago, Illinois, 60612
United States
Not yet recruiting
Oregon Health and Science University *Not yet recruiting*
Portland, Oregon, 97201
United States
Not yet recruiting
University of Pittsburgh *Not yet recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Not yet recruiting
Georgetown University Medical Center, Memory Disorders Program *Recruiting*
Washington D.C., District of Columbia, 20057
United States
Recruiting Carolyn Ward 202-784-6671
University of California, San Diego, Alzheimer's Disease Research Center *Recruiting*
La Jolla, California, 92037
United States
Recruiting Karen Wetzel 858-622-5800
University of Southern California *Not yet recruiting*
Los Angeles, California, 90033
United States
Not yet recruiting
University of California, Irvine *Recruiting*
Irvine, California, 92697
United States
Recruiting Catherine McAdams-Ortiz 949-824-8726
University of Nevada School of Medicine *Not yet recruiting*
Las Vegas, Nevada, 89102
United States
Not yet recruiting
Mount Sinai School of Medicine *Not yet recruiting*
New York City, New York, 10029
United States
Not yet recruiting
University of North Carolina *Not yet recruiting*
Chapel Hill, North Carolina, 27599
United States
Not yet recruiting
University of California *Not yet recruiting*
San Francisco, California, 94143
United States
Not yet recruiting
Additional Information:
Study ID Numbers: IA0052; IND 63,997,ADC-023
Study Start Date: April 2004
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00083590
Other Alzheimer Disease Studies:
1. Estrogen Protocol
2. A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study).
3. Study of Melatonin: Sleep Problems in Alzheimer's Disease
4. Memory Impairment Study (Mild Cognitive Impairment Study)
5. Huperzine A in Alzheimer's Disease
Related Studies:
Other Alzheimer Disease Clinical Trials
Other Nevada Clinical Trials
Other Las Vegas Clinical Trials
Huperzine A in Alzheimer's Disease
|
|
|
|
|
|
|
|
